Hospital
Usc Verdugo Hills Hospital
Usc Verdugo Hills Hospital was paid $10.03M by Medicaid between Jan 2021 and Nov 2024, across 135 billing codes. Its largest line is 0450, Emergency room services — 28% of everything it billed.
33Billing provider infoUSC VERDUGO HILLS HOSPITAL
GLENDALE, CA 91208
GLENDALE, CA 91208
33aNPI1033716147assigned 10/02/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$10.03M
24GClaims164,645
24DCodes billed135
24AFirst – last monthJan 2021 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#180 of 410
Median peer was paid$6.90M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 33,944 | $1.96M | |
| 2022 | 44,148 | $3.28M | |
| 2023 | 50,137 | $2.91M | |
| 2024incomplete | 36,416 | $1.88M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 28% | 16,374 | 15,083 | $2.82M |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 9.1% | 4,864 | 4,649 | $911K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 6.0% | 1,302 | 1,271 | $604K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 5.6% | 1,548 | 1,474 | $565K |
| 80053 | Comprehensive metabolic panel | 5.5% | 9,443 | 8,605 | $552K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.4% | 5,083 | 4,767 | $440K |
| 70450 | Computed tomography, head or brain; without contrast material | 4.4% | 1,862 | 1,824 | $439K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.8% | 6,570 | 5,990 | $283K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.6% | 758 | 661 | $256K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 2.2% | 1,270 | 1,214 | $219K |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.1% | 3,560 | 3,306 | $208K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.8% | 582 | 575 | $176K |
123 more codes
| 71045 | Radiologic examination, chest; single view | 1.6% | 5,502 | $158K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 1,884 | $110K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.0% | 10,779 | $103K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,260 | $99K |
| 99285 | Emergency room visit (most serious) | <1% | 244 | $94K |
| 99199 | Unlisted special service, procedure or report | <1% | 3,158 | $88K |
| 83690 | <1% | 3,678 | $82K | |
| 0270 | <1% | 3,981 | $75K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 568 | $74K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,547 | $71K |
| 87040 | <1% | 1,107 | $69K | |
| 83880 | <1% | 2,149 | $68K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 704 | $68K |
| 84703 | <1% | 1,539 | $67K | |
| 84484 | <1% | 1,762 | $67K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 757 | $65K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,297 | $58K |
| 84512 | <1% | 2,725 | $54K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 975 | $51K |
| 83605 | <1% | 2,081 | $50K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 2,587 | $50K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,332 | $50K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 498 | $47K |
| 81025 | <1% | 1,798 | $46K | |
| 81001 | <1% | 5,246 | $44K | |
| 85610 | <1% | 2,536 | $40K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 432 | $39K |
| 36415 | Collection of venous blood by venipuncture | <1% | 932 | $37K |
| 76830 | Ultrasound, transvaginal | <1% | 322 | $32K |
| 87077 | <1% | 1,281 | $26K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,232 | $24K |
| 93971 | <1% | 190 | $22K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 152 | $21K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 87 | $20K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 311 | $20K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 538 | $19K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,741 | $19K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,437 | $18K |
| 73630 | <1% | 354 | $17K | |
| 76770 | <1% | 202 | $16K | |
| 82948 | <1% | 1,410 | $16K | |
| 87186 | <1% | 485 | $15K | |
| 0250 | <1% | 3,465 | $15K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,688 | $15K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 625 | $15K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 649 | $15K |
| 85379 | <1% | 550 | $15K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 502 | $14K |
| 73610 | <1% | 269 | $14K | |
| 81003 | <1% | 2,175 | $14K | |
| 83735 | <1% | 956 | $13K | |
| J3490 | Unclassified drugs | <1% | 1,956 | $11K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,312 | $10K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 499 | $10K |
| 73030 | <1% | 224 | $10K | |
| 94760 | <1% | 880 | $9K | |
| 85730 | <1% | 578 | $9K | |
| 0636 | <1% | 910 | $9K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 441 | $9K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 438 | $8K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,234 | $8K |
| 84702 | <1% | 229 | $8K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 486 | $7K |
| 86900 | <1% | 616 | $7K | |
| 84100 | <1% | 696 | $6K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 195 | $6K |
| 0637 | <1% | 2,101 | $5K | |
| 80306 | <1% | 327 | $5K | |
| 86850 | <1% | 524 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 133 | $5K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 440 | $4K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 132 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 160 | $4K |
| 96376 | <1% | 263 | $3K | |
| Z7502 | <1% | 87 | $3K | |
| 86901 | <1% | 623 | $3K | |
| 90715 | <1% | 102 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 805 | $3K |
| 73130 | <1% | 78 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 14 | $3K |
| 86140 | <1% | 283 | $3K | |
| 72100 | <1% | 38 | $3K | |
| 84145 | <1% | 135 | $2K | |
| 82077 | <1% | 121 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 136 | $2K |
| 85651 | <1% | 188 | $2K | |
| 0251 | <1% | 882 | $2K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 173 | $2K |
| 73562 | <1% | 41 | $1K | |
| 80061 | Lipid panel | <1% | 292 | $1K |
| 87081 | <1% | 58 | $1K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 218 | $1K |
| A9270 | Non-covered item or service | <1% | 709 | $1K |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 86 | $1K |
| 87641 | <1% | 114 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 277 | $967.40 |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 39 | $905.75 |
| 73110 | <1% | 12 | $868.32 | |
| 85007 | <1% | 102 | $679.66 | |
| 73564 | <1% | 13 | $561.19 | |
| 73502 | <1% | 13 | $520.98 | |
| 94664 | <1% | 13 | $509.74 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 131 | $483.89 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 226 | $473.75 |
| 80143 | <1% | 41 | $464.80 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 175 | $459.40 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 40 | $451.39 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 47 | $430.17 |
| 73140 | <1% | 14 | $406.20 | |
| 80179 | <1% | 27 | $368.63 | |
| 82150 | <1% | 16 | $356.26 | |
| 0301 | <1% | 12 | $319.75 | |
| 87486 | <1% | 14 | $287.31 | |
| 84439 | <1% | 13 | $284.06 | |
| 87581 | <1% | 14 | $269.14 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 34 | $243.73 |
| 80354 | <1% | 53 | $241.18 | |
| J2704 | Injection, propofol, 10 mg | <1% | 14 | $195.98 |
| A4649 | Surgical supply; miscellaneous | <1% | 46 | $191.08 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 12 | $44.57 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13 | $32.48 |
| 82550 | <1% | 13 | $25.12 | |
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | 0% | 369 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTAYLOR, JEANNINE (SECRETARY)
| Provider | Location | Paid |
|---|---|---|
| Keck Medical Center of Usc | Los Angeles, CA | $44.98M |
| Keck Medical Center of Usc | Los Angeles, CA | $36.70M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.